Prestige Consumer Healthcare (PBH) Non-Current Debt (2011 - 2024)
Prestige Consumer Healthcare (PBH) recorded quarterly Non-Current Debt of $1.1 billion in Q1 2024, down 16.35% quarter-over-quarter from $1.3 billion in Q1 2023, and down 16.35% on a YoY basis from $1.3 billion in Q2 2023.
Prestige Consumer Healthcare (PBH) Non-Current Debt (2011 - 2024) Analysis & Trends
Prestige Consumer Healthcare's Non-Current Debt history runs 14 years deep, the most recent figure standing at $1.1 billion for Q1 2024.
- In Q1 2024, Non-Current Debt fell 16.35% year-over-year to $1.1 billion; the TTM figure through Mar 2024 stood at $1.1 billion (down 16.35% YoY), while the FY2024 annual figure was $1.1 billion, down 16.35% from the prior year.
- Non-Current Debt was $1.1 billion for Q1 2024 at Prestige Consumer Healthcare, down from $1.3 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.7 billion in Q1 2020 to a low of $1.1 billion in Q1 2024.
- Historically, Non-Current Debt has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2021.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt declined 0.2% in 2022, then dropped 16.35% in 2024.
- A 5-year view of Non-Current Debt shows it stood at $1.5 billion in 2020, then retreated by 0.22% to $1.5 billion in 2021, then declined by 4.45% to $1.5 billion in 2022, then fell by 8.86% to $1.3 billion in 2023, then decreased by 16.35% to $1.1 billion in 2024.
- The last three Non-Current Debt figures came in at $1.1 billion (Q1 2024), $1.3 billion (Q1 2023), and $1.5 billion (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 14.02 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 3.92 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.48 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 569.60 Mn |
| 10 | Prestige Consumer Healthcare | 2.37 Bn | 2.31 Bn | 157.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.13 Bn |
| Mar 31, 2024 | 1.13 Bn |
| Mar 31, 2023 | 1.35 Bn |
| Mar 31, 2023 | 1.35 Bn |
| Mar 31, 2022 | 1.48 Bn |
| Mar 31, 2022 | 1.48 Bn |
| Jun 30, 2021 | 1.55 Bn |
| Jun 30, 2021 | 1.55 Bn |
| Mar 31, 2021 | 1.48 Bn |
| Mar 31, 2021 | 1.48 Bn |
| Dec 31, 2020 | 1.55 Bn |
| Dec 31, 2020 | 1.55 Bn |
| Sep 30, 2020 | 1.55 Bn |
| Sep 30, 2020 | 1.55 Bn |
| Jun 30, 2020 | 1.62 Bn |
| Jun 30, 2020 | 1.62 Bn |
| Mar 31, 2020 | 1.73 Bn |
| Mar 31, 2020 | 1.73 Bn |
| Dec 31, 2019 | 1.70 Bn |
| Dec 31, 2019 | 1.70 Bn |